Ubrelvy Dosage
Generic name: UBROGEPANT 50mg
Dosage form: tablet
Medically reviewed by Drugs.com. Last updated on Dec 10, 2019.
2.1 Recommended Dosage
The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food.
If needed, a second dose may be taken at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
2.2 Dosage Modifications
Dosing modifications for concomitant use of specific drugs and for patients with hepatic or renal impairment are provided in Table 1.
| Dosage Modifications |
Initial Dose |
Second Dosea (if needed) |
| Concomitant Drug [see Drug Interactions (7)] | ||
| Moderate CYP3A4 Inhibitors (7.1) | 50 mg | Avoid within 24 hours |
| Weak CYP3A4 Inhibitors (7.1) | 50 mg | 50 mg |
| Strong CYP3A4 Inducers (7.2) | Avoid concomitant use | |
| Weak & Moderate CYP3A4 Inducers (7.2) | 100 mg | 100 mg |
| BCRP and/or P-gp only Inhibitors (7.3) | 50 mg | 50 mg |
| Specific Populations [see Use in Specific Populations (8)] | ||
| Severe Hepatic Impairment (Child-Pugh Class C) (8.6) | 50 mg | 50 mg |
| Severe Renal Impairment (CLcr 15-29 mL/min) (8.7) | 50 mg | 50 mg |
| End-Stage Renal Disease (CLcr <15 mL/min) (8.7) | Avoid use | |
a Second dose may be taken at least 2 hours after the initial dose
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Related questions
More about Ubrelvy (ubrogepant)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- En Español
- 27 Reviews
- Drug class: CGRP inhibitors
- FDA Approval History
